Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non Operating Income (2020 - 2023)

Historic Non Operating Income for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$777000.0.

  • Candel Therapeutics' Non Operating Income fell 12574.55% to -$777000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $452000.0, marking a year-over-year decrease of 9716.21%. This contributed to the annual value of -$21.8 million for FY2024, which is 492433.63% down from last year.
  • Latest data reveals that Candel Therapeutics reported Non Operating Income of -$777000.0 as of Q4 2023, which was down 12574.55% from $426000.0 recorded in Q3 2023.
  • Candel Therapeutics' Non Operating Income's 5-year high stood at $9.3 million during Q4 2021, with a 5-year trough of -$11.8 million in Q2 2021.
  • For the 4-year period, Candel Therapeutics' Non Operating Income averaged around $105266.7, with its median value being $193000.0 (2022).
  • As far as peak fluctuations go, Candel Therapeutics' Non Operating Income crashed by 448326.85% in 2021, and later soared by 414712.04% in 2022.
  • Candel Therapeutics' Non Operating Income (Quarter) stood at -$4.4 million in 2020, then skyrocketed by 314.47% to $9.3 million in 2021, then crashed by 67.67% to $3.0 million in 2022, then plummeted by 125.75% to -$777000.0 in 2023.
  • Its Non Operating Income stands at -$777000.0 for Q4 2023, versus $426000.0 for Q3 2023 and -$35000.0 for Q2 2023.